SIS
ALXN

Sound Income Strategies’s Alexion Pharmaceuticals ALXN Stock Holding History

Sound Income Strategies’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-40
Closed -$6.12K – 1086
2021
Q1 		$6.12K Hold
40
– – ﹤0.01% 584
2020
Q4 		$6K Hold
40
– – ﹤0.01% 569
2020
Q3 		$5K Hold
40
– – ﹤0.01% 558
2020
Q2 		$4K Buy
+40
New +$4.25K ﹤0.01% 557

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Sound Income Strategies's ALXN Position: Q2 2021 in Review

Sound Income Strategies sold out of Alexion Pharmaceuticals (ALXN) in Q2 2021, closing a stake of 40 shares — an estimated $6.12K sold.

Sound Income Strategies first reported a position in ALXN in Q2 2020 and held it in 4 quarters. The position peaked at $6.12K in Q1 2021. 708 funds tracked by Wall St. Rank hold ALXN as of Q2 2021.

  • Sound Income Strategies reported no remaining Alexion Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Sound Income Strategies sold 40 Alexion Pharmaceuticals shares in Q2 2021, an estimated $6.12K.
  • Sound Income Strategies first reported a position in Alexion Pharmaceuticals in Q2 2020 and held it in 4 quarters.
  • Sound Income Strategies's Alexion Pharmaceuticals position peaked at $6.12K in Q1 2021.
  • 708 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2021.

Based on Sound Income Strategies's 13F filing for Q2 2021, filed 13 Jul 2021.